Pharma News

Addex Therapeutics announced the results of the mGlu5 receptor occupancy study with dipraglurant in healthy volunteers. The study was conducted under the direction of lead investigator professor of neurology, Dean F. Wong, MD, PhD of the Departments of Radiology, Psychiatry and Neuroscience at Johns Hopkins University.

Mylan N.V. announced the U.S. launch of Metoprolol Tartrate Tablets USP, 37.5 mg and 75 mg, which is the generic version of Novartis' Lopressor® Tablets. These strengths are the first and only available intermediate dosage strengths between the existing Metoprolol Tartrate Tablets USP strengths of 25 mg, 50 mg and 100 mg. Mylan currently is the only manufacturer that offers Metoprolol Tartrate Tablets in five strengths.

A common antihistamine used to treat symptoms of allergies and the common cold, called clemastine fumarate, partially reversed damage to the visual system in people with multiple sclerosis (MS) in a preliminary study released today that will be presented today at the American Academy of Neurology's 68th Annual Meeting in Vancouver, Canada, April 15 to 21, 2016.

New research led by Professor Cathie Martin of the John Innes Centre has revealed how a plant used in traditional Chinese medicine produces compounds which may help to treat cancer and liver diseases.

Depression, metabolic factors combine to boost risk of developing diabetes, study findsDepression may compound the risk of developing type 2 diabetes in people with such early warning signs of metabolic disease as obesity, high blood pressure and unhealthy cholesterol levels, according to researchers from McGill University, l'Université de Montréal, the Institut de recherches cliniques de Montréal and the University of Calgary.

The increasing incidence of Alzheimer's disease (AD), improving diagnostic technologies and the prospect of new therapies are driving the global AD market. BCC Research reveals in its new report the need for effective treatments has become more urgent, especially given the recurrent failure of several prominent disease-modifying agents in late-stage development.

AstraZeneca and Eli Lilly and Company announced that AMARANTH, a Phase II/III study of AZD3293, an oral beta secretase cleaving enzyme (BACE) inhibitor currently in development as a potential treatment for early Alzheimer’s disease, will continue into Phase III of the Phase II/III seamless trial.

The U.S. Food and Drug Administration approved Venclexta (venetoclax) for the treatment of patients with chronic lymphocytic leukemia (CLL) who have a chromosomal abnormality called 17p deletion and who have been treated with at least one prior therapy. Venclexta is the first FDA-approved treatment that targets the B-cell lymphoma 2 (BCL-2) protein, which supports cancer cell growth and is overexpressed in many patients with CLL.

The Medicines Company announced that the U.S. Food and Drug Administration ( FDA ) has granted Fast Track Designation to the investigational agent CARBAVANCE® (meropenem-vaborbactam) for the treatment of complicated urinary tract infections (cUTI). CARBAVANCE is the combination of the carbapenem antibiotic, meropenem, with the novel beta-lactamase inhibitor, vaborbactam (formerly known as RPX7009), that is being developed for the treatment of gram-negative infections, including those due to carbapenem-resistant Enterobacteriaceae (CRE).